

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-604

CHEMISTRY REVIEW(S)



NDA 21-604

Children's ElixSure™ Ibuprofen Oral Suspension

Taro Pharmaceuticals USA Inc.

Vispi P. Bhavnagri

HFD 550

HFD 560



Table of Contents

Table of Contents	2
Chemistry Review Data Sheet.....	5
The Executive Summary	9
I. Recommendations	9
A. Recommendation and Conclusion on Approvability	9
B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approval	9
II. Summary of Chemistry Assessments	9
A. Description of the Drug Substance (s) and Drug Product (s)	9
B. Description of How the Drug Product is Intended to be Used	9
C. Basis for Approvability or Not-Approval Recommendation	10
III. Administrative	10
A. Reviewer's Signature:	10
B. Endorsement Block:	10
C. CC Block:	10
<u>Chemistry Assessment</u>	11
A DRUG SUBSTANCE.....	11
1. Description & Characterization	11
a. Description.....	11
b. Characterization / Proof Of Structure	11
2. Manufacturer	11
3. Synthesis / Method Of Manufacture	12
a. Starting Materials - Specs & Tests.....	12
b. Solvents, Reagents, etc.....	12



c. Flow Chart.....	12
d. Detailed Description.....	12
4. Process Controls.....	12
a. Reaction Completion / Other In-Process Tests.....	12
b. Intermediate Specs & Tests.....	12
5. Reference Standard	13
a. Preparation.....	13
b. Specifications.....	13
6. Regulator Specifications / Analytical Methods	13
a. Drug Substance Specifications & Tests	13
b. Purity Profile.....	15
c. Microbiology.....	15
7. Container/Closure System For Drug Substance Storage.....	15
8. Drug Substance Stability.....	15
B. DRUG PRODUCT	16
1/2. Components/Composition.....	16
3. Specifications & Methods For Drug Product Ingredients	16
a: Active Ingredient.....	16
b. Inactive Ingredients	16
4. Manufacturer	17
5. Methods Of Manufacturing And Packaging.....	18
a. Production Operations.....	18
b. In-Process Controls & Tests.....	20
c. Reprocessing Operations	20
6. Regulatory Specifications And Methods For Drug Product.....	20
a. Sampling Procedures	21
b. Regulatory Specifications and Analytical Procedures	21
7. Container/Closure System.....	27
8. Microbiology.....	31
9. Drug Product Stability	31
C. INVESTIGATIONAL FORMULATIONS	36



CHEMISTRY REVIEW



D. ENVIRONMENTAL ASSESSMENT.....	36
E. METHODS VALIDATION.....	36
F. LABELING	36
G. ESTABLISHMENT INSPECTION.....	37
H. DRAFT DEFICIENCY LETTER	37



Chemistry Review Data Sheet

1. NDA 21-604
2. REVIEW #: 1
3. REVIEW DATE: 8-Oct-2002
4. REVIEWER: Vispi P. Bhavnagri
5. PREVIOUS DOCUMENTS:

Previous Documents

IND 62,832

Document Date

Aug-2-2002

6. SUBMISSION(S) BEING REVIEWED:

Submission(s) Reviewed

Original

Minor Chem. Amendment (BC)

Multidisciplinary Amendment (BZ)

Minor Chem. Amendment (BC)

Minor Chem. Amendment (BC)

Minor Chem. Amendment (BC)

Document Date

30-Dec-2002

24-Jan-2003

31-Jan-2003

7-Mar-2003

20-Jun-2003

27-Jun-2003

22-Jul-2003

23-Sep-2003

30-Sep-2003

1-Oct-2003

8-Oct-2003

23-Oct-2003

7. NAME & ADDRESS OF APPLICANT:

Name: Taro Pharmaceutical USA, Inc.

Address: Five Skyline Drive, Hawthorne, NY 10532



CHEMISTRY REVIEW



Chemistry Review Data Sheet

Representative: Kalpana Rao, Vice President, Regulatory Affairs

Telephone: 914-345-9001 ext. 298

8. DRUG PRODUCT NAME/CODE/TYPE:

- a) Proprietary Name : Children's ElixSure™ Ibuprofen Oral Suspension
- b) Non-Proprietary Name (USAN): Ibuprofen
- c) Code Name/# (ONDC only): N/A
- d) Chem. Type/Submission Priority (ONDC only):
 - Chem. Type: 3
 - Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION:

505 (b)(2)

10. PHARMACOL. CATEGORY:

Analgesic and antipyretic

11. DOSAGE FORM:

Suspension

12. STRENGTH/POTENCY:

100 mg/5 mL

13. ROUTE OF ADMINISTRATION:

Oral

14. Rx/OTC DISPENSED: ___ Rx ___ X ___ OTC


15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):

___ SPOTS product – Form Completed

___ X ___ Not a SPOTS product

Chemistry Review Data Sheet

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

Benzeneacetic acid, α -methyl-4-(2-methylpropyl), (\pm)(\pm)- p-Isobutylhydratropic acid.(\pm)-2-(p-Isobutylphenyl)propionic acid.

$C_{13}H_{18}O_2$
206.28

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

DMF #	TYPE	HOLDER	ITEM REFERENCED	CODE ¹	STATUS ²	DATE REVIEW COMPLETED	COMMENTS
[Large handwritten mark]	II	[Large handwritten mark]	[Large handwritten mark]	3	Adequate	4/25/03	
	II			4	N/A		
	III			4	N/A		
	III			4	N/A		
	III			4	N/A		
	III			4	N/A		



CHEMISTRY REVIEW



Chemistry Review Data Sheet

DMF #	TYPE	HOLDER	ITEM REFERENCE ^{FD}	CODE ¹	STATUS ²	DATE REVIEW COMPLETED	COMMENTS
1	III	[Handwritten signature]	[Handwritten signature]	4	N/A		
1	III			4	N/A		

¹ Action codes for DMF Table:

1 – DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

2 – Type 1 DMF

3 – Reviewed previously and no revision since last review

4 – Sufficient information in application

5 – Authority to reference not granted

6 – DMF not available

7 – Other (explain under "Comments")

² Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:

DOCUMENT	APPLICATION NUMBER	DESCRIPTION
IND	62,832	

18. STATUS:

CONSULTS/ CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Biometrics	NA	NA	NA
EES	Acceptable	9/29/03	S. Adams
Pharm/Tox	Approval	8/19/03	Conrad Chen
Biopharm	Acceptable	10/25/03	Lei Zhang
LNC	Acceptable	10/24/03	Linda Kim-Jung
Methods Validation	Will be sent to FDA Lab		
OPDRA	N/A		
EA	Categorical Exclusion		
Microbiology	N/A		

The Chemistry Review for NDA 21-604

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

This NDA can be approved from a CMC standpoint.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approval

None.

II. Summary of Chemistry Assessments

A. Description of the Drug Substance (s) and Drug Product (s)

Drug Substance:

Ibuprofen is manufactured and supplied by . The manufacture and control of the drug substance were referenced to DMF. The DMF has been recently reviewed and found to be adequate. Test and acceptance criteria meet and in some cases exceeded the requirements of the USP.

Drug Product:

The drug product is a berry flavored pediatric ibuprofen suspension containing 100 mg of ibuprofen per 5 mL of the suspension. Though almost all the components of the formulation are USP or NF articles, the formulation is unique in that it is thixotropic, thus it flows on to the spoon when the bottle is squeezed but gels on the spoon so that it can be administered to children without spilling. The manufacture of the drug product does not require many controls. However, the control of the pH between 4.9 and 5.7 pH units is critical to the flow properties of the drug product.

B. Description of How the Drug Product is Intended to be Used

The drug product is intended for oral administration. Five mL of the suspension contains 100 mg of ibuprofen. The dose is 5 mL to 15 mL three to four times a day. It is administered with a special plastic spoon that has 5 and 2.5 mL markings on it (part of the container closure system).



Executive Summary Section

The company has asked for a 24 month expiration period based on 24 months of room temperature stability data (25° C/60% RH). An expiration period of 24 months can be granted based on the stability results submitted. The company eventually intends to have a shelf life of 5 years for this product.

C. Basis for Approvability or Not-Approval Recommendation

Ibuprofen is a USP article and has been in use for a long time. The acceptance criteria for the drug substance used in this drug product has additional tests and acceptance criteria over and above those in the USP. The acceptance criteria for some of the USP tests are also more stringent.

The only critical control during the manufacturing of the dosage form is pH, which must be within certain limits if the drug product is to have the desired flow properties. The stability of the dosage form over 24 months does not show any instability trends that would be cause for alarm. The applicant was asked to and has complied with tightening the dissolution and other acceptance criteria thereby ensuring consistency in the quality, strength and potency of the drug product.

There is one drug substance and one drug product manufacturing facility and a number of contract labs performing analytical procedures for the various components of the drug product. All of these facilities were found to be acceptable. An overall "Acceptable" recommendation was issued by Compliance on 9/29/03.

The company has asked for a categorical exclusion under the provisions of 21 CFR 25.3(a), which is acceptable.

III. Administrative

A. Reviewer's Signature:

N/A

B. Endorsement Block:

N/A

C. CC Block:

N/A

40 Page(s) Withheld

§ 552(b)(4) Trade Secret / Confidential

§ 552(b)(4) Draft Labeling

§ 552(b)(5) Deliberative Process

Withheld Track Number: Chemistry-

1 of 1

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Vispi Bhavnagri
10/28/03 03:07:31 PM
CHEMIST

John Smith
10/28/03 03:14:10 PM
CHEMIST